CLAIM CARDS
Claim Cards
Atomic claims extracted from accepted Researka artifacts, with source support, contradiction state, and provenance links when available.
Filtered to publication 89707573-02b4-4757-8c0d-0454119a5cb3
exploratory
The cited A/B receipts support a specific working claim: Use of metformin was associated with a significantly better overall and progression-free survival of patients with WHO grade III glioma (HR for OS = 0.30; 95% CI = 0.11-0.81); HR for PFS = 0.29; 95% CI = 0.11-0.78. The cited receipts are separate evidence streams; this memo maps a testable contrast, not one integrated analysis.
Contradiction: none
Sources: 5
exploratoryInterpretation note:** This is a hypothesis-generating alpha memo, not confirmatory evidence; subgroup or context-derived claims require independent replication.
Contradiction: none
Sources: 5
exploratoryMetformin's clinical effects are stratified by disease pathology and acuity, as shown by its selective survival benefit in WHO grade III but not grade IV glioma and its consistent mortality reduction in acute sepsis and COVID-19, suggesting context-dependent mechanisms that challenge uniform therapeutic application.
Contradiction: none
Sources: 5
exploratory_No A_core/B_context counter-evidence found in this run; treat this as a single-direction signal until a broader receipt expansion finds a real opposing fact._
Contradiction: none
Sources: 5
exploratorySuggested citation:** Dom Lynch. (2026). Stage-Specific Efficacy of Metformin in High-Grade Glioma. ReseaRka Evidence Index. Version 1.0.
Contradiction: none
Sources: 5
exploratoryPriority note:** This memo records the first published framing, source bundle, and evidence receipts for this run. Reuse should cite the canonical version.
Contradiction: none
Sources: 5